This pipeline uses various statistical tests to identify mRNAs whose expression levels correlated to selected clinical features.
Testing the association between 18090 genes and 7 clinical features across 171 samples, statistically thresholded by Q value < 0.05, 7 clinical features related to at least one genes.
-
5 genes correlated to 'Time to Death'.
-
ARHGAP12|94134 , KCTD18|130535 , ZNF25|219749 , PRKAR2B|5577 , EID1|23741
-
5 genes correlated to 'AGE'.
-
ACOX2|8309 , MCHR1|2847 , TCEAL5|340543 , MAOB|4129 , PHKA1|5255
-
55 genes correlated to 'PRIMARY.SITE.OF.DISEASE'.
-
TMEM156|80008 , CD38|952 , P2RY10|27334 , IGJ|3512 , POU2AF1|5450 , ...
-
18 genes correlated to 'GENDER'.
-
ZFY|7544 , PRKY|5616 , CYORF15B|84663 , RPS4Y1|6192 , XIST|7503 , ...
-
4 genes correlated to 'DISTANT.METASTASIS'.
-
CLDN6|9074 , CXADRP3|440224 , PRPS1|5631 , LRRC28|123355
-
6 genes correlated to 'LYMPH.NODE.METASTASIS'.
-
IHH|3549 , NPAS4|266743 , MUC6|4588 , AMY1A|276 , NXNL2|158046 , ...
-
1 gene correlated to 'NEOPLASM.DISEASESTAGE'.
-
SLC34A2|10568
Complete statistical result table is provided in Supplement Table 1
Clinical feature | Statistical test | Significant genes | Associated with | Associated with | ||
---|---|---|---|---|---|---|
Time to Death | Cox regression test | N=5 | shorter survival | N=0 | longer survival | N=5 |
AGE | Spearman correlation test | N=5 | older | N=0 | younger | N=5 |
PRIMARY SITE OF DISEASE | ANOVA test | N=55 | ||||
GENDER | t test | N=18 | male | N=14 | female | N=4 |
DISTANT METASTASIS | ANOVA test | N=4 | ||||
LYMPH NODE METASTASIS | ANOVA test | N=6 | ||||
NEOPLASM DISEASESTAGE | ANOVA test | N=1 |
Time to Death | Duration (Months) | 0.2-357.4 (median=47.5) |
censored | N = 81 | |
death | N = 87 | |
Significant markers | N = 5 | |
associated with shorter survival | 0 | |
associated with longer survival | 5 |
HazardRatio | Wald_P | Q | C_index | |
---|---|---|---|---|
ARHGAP12|94134 | 0.62 | 4.705e-07 | 0.0085 | 0.35 |
KCTD18|130535 | 0.45 | 7.166e-07 | 0.013 | 0.358 |
ZNF25|219749 | 0.64 | 7.183e-07 | 0.013 | 0.345 |
PRKAR2B|5577 | 0.72 | 9.341e-07 | 0.017 | 0.35 |
EID1|23741 | 0.52 | 1.811e-06 | 0.033 | 0.355 |
AGE | Mean (SD) | 56.07 (16) |
Significant markers | N = 5 | |
pos. correlated | 0 | |
neg. correlated | 5 |
SpearmanCorr | corrP | Q | |
---|---|---|---|
ACOX2|8309 | -0.414 | 2e-08 | 0.000362 |
MCHR1|2847 | -0.3914 | 1.43e-07 | 0.00259 |
TCEAL5|340543 | -0.3816 | 2.828e-07 | 0.00512 |
MAOB|4129 | -0.3667 | 8.702e-07 | 0.0157 |
PHKA1|5255 | -0.3584 | 1.6e-06 | 0.0289 |
PRIMARY.SITE.OF.DISEASE | Labels | N |
DISTANT METASTASIS | 25 | |
PRIMARY TUMOR | 1 | |
REGIONAL CUTANEOUS OR SUBCUTANEOUS TISSUE (INCLUDES SATELLITE AND IN-TRANSIT METASTASIS) | 33 | |
REGIONAL LYMPH NODE | 112 | |
Significant markers | N = 55 |
ANOVA_P | Q | |
---|---|---|
TMEM156|80008 | 8.12e-10 | 1.47e-05 |
CD38|952 | 2.456e-09 | 4.44e-05 |
P2RY10|27334 | 7.728e-09 | 0.00014 |
IGJ|3512 | 8.469e-09 | 0.000153 |
POU2AF1|5450 | 2.572e-08 | 0.000465 |
ADAM6|8755 | 4.595e-08 | 0.000831 |
FCRL3|115352 | 6.453e-08 | 0.00117 |
CD79A|973 | 6.921e-08 | 0.00125 |
FCRL5|83416 | 8.919e-08 | 0.00161 |
PRKCB|5579 | 1.015e-07 | 0.00183 |
GENDER | Labels | N |
FEMALE | 66 | |
MALE | 105 | |
Significant markers | N = 18 | |
Higher in MALE | 14 | |
Higher in FEMALE | 4 |
T(pos if higher in 'MALE') | ttestP | Q | AUC | |
---|---|---|---|---|
ZFY|7544 | 30.42 | 9.377e-67 | 1.7e-62 | 0.9914 |
PRKY|5616 | 26.47 | 2.425e-55 | 4.39e-51 | 0.9939 |
CYORF15B|84663 | 33.13 | 2.911e-53 | 5.26e-49 | 1 |
RPS4Y1|6192 | 29.46 | 5.202e-45 | 9.41e-41 | 1 |
XIST|7503 | -19.63 | 4.961e-43 | 8.97e-39 | 0.9711 |
DDX3Y|8653 | 30.82 | 4.889e-42 | 8.84e-38 | 0.9976 |
KDM5D|8284 | 29.08 | 1.807e-36 | 3.27e-32 | 0.9921 |
EIF1AY|9086 | 28.78 | 3.519e-31 | 6.36e-27 | 0.9952 |
TSIX|9383 | -15.1 | 5.704e-30 | 1.03e-25 | 0.9701 |
USP9Y|8287 | 25.67 | 1.282e-26 | 2.32e-22 | 0.999 |
DISTANT.METASTASIS | Labels | N |
M0 | 148 | |
M1 | 2 | |
M1A | 2 | |
M1B | 2 | |
M1C | 2 | |
Significant markers | N = 4 |
ANOVA_P | Q | |
---|---|---|
CLDN6|9074 | 1.254e-09 | 2.27e-05 |
CXADRP3|440224 | 4.405e-08 | 0.000796 |
PRPS1|5631 | 1.462e-06 | 0.0264 |
LRRC28|123355 | 2.33e-06 | 0.0421 |
LYMPH.NODE.METASTASIS | Labels | N |
N0 | 95 | |
N1 | 2 | |
N1A | 6 | |
N1B | 16 | |
N2 | 1 | |
N2A | 4 | |
N2B | 10 | |
N2C | 5 | |
N3 | 16 | |
NX | 2 | |
Significant markers | N = 6 |
ANOVA_P | Q | |
---|---|---|
IHH|3549 | 2.079e-11 | 3.76e-07 |
NPAS4|266743 | 1.613e-07 | 0.00292 |
MUC6|4588 | 8.804e-07 | 0.0159 |
AMY1A|276 | 9.125e-07 | 0.0165 |
NXNL2|158046 | 9.49e-07 | 0.0172 |
WBSCR17|64409 | 2.149e-06 | 0.0389 |
NEOPLASM.DISEASESTAGE | Labels | N |
I OR II NOS | 4 | |
STAGE I | 17 | |
STAGE IA | 10 | |
STAGE IB | 14 | |
STAGE II | 19 | |
STAGE IIA | 8 | |
STAGE IIB | 10 | |
STAGE IIC | 8 | |
STAGE III | 9 | |
STAGE IIIA | 5 | |
STAGE IIIB | 17 | |
STAGE IIIC | 23 | |
STAGE IV | 6 | |
Significant markers | N = 1 |
ANOVA_P | Q | |
---|---|---|
SLC34A2|10568 | 7.425e-07 | 0.0134 |
-
Expresson data file = SKCM-TM.uncv2.mRNAseq_RSEM_normalized_log2.txt
-
Clinical data file = SKCM-TM.clin.merged.picked.txt
-
Number of patients = 171
-
Number of genes = 18090
-
Number of clinical features = 7
For survival clinical features, Wald's test in univariate Cox regression analysis with proportional hazards model (Andersen and Gill 1982) was used to estimate the P values using the 'coxph' function in R. Kaplan-Meier survival curves were plot using the four quartile subgroups of patients based on expression levels
For continuous numerical clinical features, Spearman's rank correlation coefficients (Spearman 1904) and two-tailed P values were estimated using 'cor.test' function in R
For multi-class clinical features (ordinal or nominal), one-way analysis of variance (Howell 2002) was applied to compare the log2-expression levels between different clinical classes using 'anova' function in R
For two-class clinical features, two-tailed Student's t test with unequal variance (Lehmann and Romano 2005) was applied to compare the log2-expression levels between the two clinical classes using 't.test' function in R
For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.
This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.